公开(公告)号：US11819519B2

公开(公告)日：2023-11-21

申请号：US17270943

申请日：2019-08-26

Applicant: HANGZHOU CONVERD CO., LTD. ,  Yafei Hou

Inventor： Fang Hu ,  Yafei Hou ,  Jipo Sheng ,  Xiankui Tan

IPC: A61K35/17 ,  C12N7/00 ,  C07K14/74 ,  C07K14/725 ,  A61P35/00 ,  A61K35/768 ,  A61K38/17 ,  A61K38/28 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K35/768 ,  A61K38/1774 ,  A61K38/28 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C12N7/00

Abstract: A therapeutic agent comprising a nucleic acid and a TCR modified immune cell and use thereof. The therapeutic agent comprises a first composition comprising a first active ingredient and a second composition comprising a second active ingredient. The first active ingredient includes or contains a nucleic acid having a labeling polypeptide coding sequence for being introduced into a tumor cell and/or a cancer cell. The labeling polypeptide has one or more epitope polypeptides which can be presented on a surface of the tumor cell and/or cancer cell by MHC class I molecules. The second composition comprises a second active ingredient in a second pharmaceutically acceptable carrier and the second active ingredient comprises a T cell receptor modified immune cell which can specifically recognize and bind to the epitope polypeptide presented by MHC class I molecules. The therapeutic agent achieves synergistic treatment effect and provides a new route for tumor treatment.

公开(公告)号：US10980859B2

公开(公告)日：2021-04-20

申请号：US15058456

申请日：2016-03-02

Applicant: Hangzhou Converd Co., Ltd.

Inventor： Fang Hu ,  Ronghua Zhao ,  Siyi Chen ,  Bo Wu ,  Huiqun Xia ,  Yanjun Zheng

IPC: A61K38/19 ,  A61K35/761 ,  A61K45/06 ,  A61K31/513 ,  A61K31/7068 ,  A61K31/704 ,  A61K33/24 ,  A61K31/475 ,  A61K35/768 ,  A61K38/48 ,  A61K35/763 ,  A61K35/74 ,  A61K38/55 ,  A61K35/766 ,  C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  C12N7/00 ,  A61K39/00

Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.

公开(公告)号：US20200289591A1

公开(公告)日：2020-09-17

申请号：US16650076

申请日：2018-06-28

Applicant: Hangzhou Converd Co., Ltd.

Inventor： Jin Fu ,  Ronghua Zhao ,  Rong Zhang ,  Tingting Wang ,  Lin Chen ,  Fang Hu

IPC: A61K35/768 ,  C12N7/00 ,  A61P35/00

Abstract: The invention provides an isolated recombinant oncolytic vaccinia virus, pharmaceutical compositions and uses thereof for drugs for treatment of tumors and/or cancers. The isolated recombinant oncolytic vaccinia virus is functionally deficient in the TK gene and the VGF gene, and the genome of the recombinant oncolytic vaccinia virus is integrated with an exogenous IL-21 gene, and wherein the IL-21 gene is capable of being expressed in tumor cells. The recombinant oncolytic vaccinia virus can selectively replicate in tumor cells, and can also fully exert the anti-tumor immune effect of the exogenous IL-21, such that the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation effect of IL-21 achieve a synergic effect.

公开(公告)号：US20200289567A1

公开(公告)日：2020-09-17

申请号：US16798465

申请日：2020-02-24

Applicant: SYNIMMUNE, INC. ,  HANGZHOU CONVERD CO., LTD.

Inventor： Yafei Hou ,  Fang Hu ,  Jipo Sheng ,  Xiankui Tan ,  Can Chen

IPC: A61K35/17 ,  A61K39/00 ,  A61K35/768 ,  A61K38/28 ,  A61K38/17

Abstract: A therapeutic agent and method of administering the therapeutic agent for the treatment of tumors and/or cancers of a subject, the therapeutic agent comprising a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide comprising one or more antigenic epitope peptides and/or encoding a MHC protein; a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro; wherein the nucleic acid when administered to the subject as part of the pharmaceutical composition causes the tumor cells and/or cancer cells of the subject to express the one or more antigenic epitope peptides to elicit an immune response of the immune cells.

公开(公告)号：US11806374B2

公开(公告)日：2023-11-07

申请号：US16650863

申请日：2018-07-03

Applicant: HANGZHOU CONVERD CO., LTD.

Inventor： Jipo Sheng ,  Jin Fu ,  Ronghua Zhao ,  Yun Qin ,  Lin Chen ,  Sanmao Kang ,  Fang Hu

IPC: A61K39/23 ,  C12N15/79 ,  C07H21/04 ,  A61K35/761 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N15/63 ,  A61K48/00 ,  C12N15/64

CPC classification number: A61K35/761 ,  A61K48/005 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/63 ,  C12N15/64 ,  C12N2310/531 ,  C12N2710/10332 ,  C12N2710/10343

Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.

公开(公告)号：US11786552B2

公开(公告)日：2023-10-17

申请号：US16798465

申请日：2020-02-24

Applicant: HANGZHOU CONVERD CO., LTD. ,  Yafei Hou

Inventor： Yafei Hou ,  Fang Hu ,  Jipo Sheng ,  Xiankui Tan ,  Can Chen

IPC: A61K35/17 ,  A61K39/00 ,  A61K35/768 ,  A61K38/28 ,  A61K38/17 ,  A61P35/00 ,  C07K14/725 ,  C07K14/74 ,  C12N7/00

CPC classification number: A61K35/17 ,  A61K35/768 ,  A61K38/1774 ,  A61K38/28 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C12N7/00

Abstract: A therapeutic agent and method of administering the therapeutic agent for the treatment of tumors and/or cancers of a subject, the therapeutic agent comprising a first pharmaceutical composition comprising a first active ingredient in a first druggable vehicle, wherein the first active ingredient comprises a nucleic acid encoding a labelling polypeptide comprising one or more antigenic epitope peptides and/or encoding a MHC protein; a second pharmaceutical composition comprising a second active ingredient in a second druggable vehicle, wherein the second active ingredient comprises immune cells purified from peripheral blood or from tumor tissue and are cultured in vitro; wherein the nucleic acid when administered to the subject as part of the pharmaceutical composition causes the tumor cells and/or cancer cells of the subject to express the one or more antigenic epitope peptides to elicit an immune response of the immune cells.

公开(公告)号：US11357804B2

公开(公告)日：2022-06-14

申请号：US16478727

申请日：2018-01-24

Applicant: HANGZHOU CONVERD CO., LTD.

Inventor： Ronghua Zhao ,  Yanjun Zheng ,  Fang Hu

IPC: A61K35/761 ,  A61P37/02 ,  A61P35/00 ,  C12N7/00

Abstract: Provided is the use of selectively replicating oncolytic viruses in the preparation of immunostimulants for treatment of tumors and/or cancers, wherein the oncolytic viruses do not carry exogenous immunoregulatory genes.

公开(公告)号：US11446345B2

公开(公告)日：2022-09-20

申请号：US16474349

申请日：2018-01-03

Applicant: HANGZHOU CONVERD CO., LTD.

Inventor： Fang Hu ,  Lin Chen ,  Ronghua Zhao

IPC: A61K35/761 ,  A61P35/00 ,  A61K35/17 ,  A61K35/768 ,  A61K35/763 ,  A61K35/765 ,  A61K35/766 ,  A61K35/76

Abstract: The present disclosure provides therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic virus that selectively replicate in tumor cells and comprise NK cells.

公开(公告)号：US20160250292A1

公开(公告)日：2016-09-01

申请号：US15058456

申请日：2016-03-02

Applicant: Hangzhou Converd Co., Ltd.

Inventor： Fang Hu ,  Ronghua Zhao ,  Siyi Chen ,  Bo Wu ,  Huiqun Xia ,  Yanjun Zheng

IPC: A61K38/19 ,  C12N7/00 ,  A61K39/395 ,  C07K16/30 ,  A61K35/761 ,  C07K16/28

CPC classification number: A61K38/193 ,  A61K31/475 ,  A61K31/513 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/24 ,  A61K35/74 ,  A61K35/761 ,  A61K35/763 ,  A61K35/766 ,  A61K35/768 ,  A61K38/191 ,  A61K38/4873 ,  A61K38/55 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K2317/76 ,  C12N7/00 ,  C12N2710/10332 ,  Y02A50/466 ,  Y02A50/484 ,  A61K2300/00

Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.

Abstract translation: 本发明提供一种体内个体化的全身免疫治疗方法和装置。 该方法以非顺序方式包括：（1）增加肿瘤部位肿瘤抗原的释放量; （2）在肿瘤部位，增加能够粘附和/或包裹肿瘤抗原的蛋白质水平; （3）在肿瘤部位增加参与免疫的专用抗原呈递细胞的水平，并且在专用抗原呈递细胞和免疫效应细胞之间建立能够激活免疫效应细胞的紧密连接; 和（4）在肿瘤部位，增加免疫效应细胞的水平和改善功能。 步骤（1） - （4）各自在最大相互重叠的相应时间以及最大重叠的相应位置处达到最大值。 本发明结合了溶瘤治疗和免疫治疗，在个体化的全身免疫治疗中，提供了显着改善的治疗效果。